It’s the same question sickle cell patients ... begun the gene therapy treatment. At Children’s National — which was ahead of the curve after it participated in Bluebird Bio’s clinical ...

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say Bluebird bio will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on ...

US biotech bluebird bio has announced plans to split ... manufacturing standards for its lead gene therapy product, Lentiglobin, in sickle cell anaemia that could hold up filing until late 2022.

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio ... therapy for neurological disease CALD The US FDA has cleared two novel gene therapies for sickle ...

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe ... autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...